Reading disorder

Summary

Reading disorder (MONDO:0001697) is a disease and 7 clinical trials. Top therapeutic interventions include atomoxetine hydrochloride. A subtype of learning disability — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	reading disorder
Mondo ID	MONDO:0001697
DOID	DOID:13365
SNOMED CT	52824009
Is cancer (heuristic)	no

Disease family

This is a subtype of learning disability. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › developmental disorder of mental health › specific developmental disorder › learning disability › reading disorder

Related subtypes (2): writing disorder, dyscalculia

Subtypes (3): alexia, dyslexia, hyperlexia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00191906	PHASE4	COMPLETED	Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
NCT05854082	PHASE4	COMPLETED	Impact of Motor Tasks and Lidocaine on Reading Unfamiliar Words in Adults With and Without Dyslexia
NCT06213272	Not specified	RECRUITING	Combined Exercise and Targeted Therapy for Post-Stroke Reading Deficits
NCT02107534	Not specified	UNKNOWN	Group-based Training for Parents of Children With Dyslexia
NCT04113707	Not specified	WITHDRAWN	Building Long-term Academic Success Through Ongoing Fun Fitness Program
NCT05137353	Not specified	COMPLETED	A Multisensory Music Intervention for Children With Reading Disorders (RitMoZ)
NCT06186882	Not specified	UNKNOWN	Gene x Environment Interplay in Developmental Dyslexia Treatment: A Round-trip Translation Between Humans and Animal

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ATOMOXETINE HYDROCHLORIDE	4	1